Eli Lilly has agreed to acquire Calytrix Bio in a deal worth up to $1.5 billion in cash, expanding Lilly’s presence in rare blood cancers.
Calytrix’s lead program is a preclinical biparatopic antibody targeting mutant calreticulin (mCALR), for essential thrombocythemia and myelofibrosis.
The total includes an undisclosed upfront payment and additional payments tied to clinical and regulatory milestones. The companies have not disclosed the upfront amount or expected closing date.
Founded in 2025 by J.P. Morgan Life Sciences Private Capital, Calytrix also received backing from Westlake BioPartners and Avoro Ventures.
The candidate remains preclinical, so it has not yet been shown to be safe or effective in people. The deal is a pipeline bet, not an approval or near-term treatment launch.
Sources:
Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix
Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion
Lilly to buy Calytrix Bio for up to $1.5 billion
Lilly to buy Calytrix Bio for up to $1.5 billion
Eli Lilly Makes $1.5 Billion Move Beyond Weight-Loss Drugs
Lilly expands myeloproliferative neoplasm presence with up to $1.5B Calytrix buy
Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
Eli Lilly to acquire Calytrix Bio in deal worth up to $1.5 billion
Lilly Bets Up to $1.5 Billion on Calytrix's Preclinical Antibody
Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion
Lilly strikes again, buying Calytrix in $1.5bn deal
Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion
Lilly to acquire Calytrix Bio for up to USD 1.5 billion in ...